Source Ce Certified Injectable Dermal Filler for Lips, Wrinkles, Contours

CE Certified Injectable Dermal Filler Sourcing Guide

Procurement professionals must first distinguish between products marketed for external cosmetic application and those intended for clinical injection. The observed listings reveal a confusing mix of attributes, including items labeled for "Salon, Home" use alongside those specifying "Injection & Puncture Instrument" usage. Buyers must rigorously verify the intended mode of administration before proceeding, as the regulatory requirements for injectable biological reagents differ significantly from topical gels. Misinterpreting these usage modes can lead to compliance failures and safety risks in the supply chain.

The product scope also encompasses diverse functional claims ranging from wrinkle removal to breast enhancement, which requires careful scrutiny of the specific formulation. While some entries list "Sodium Cross-Linked Hyaluronic Acid" as the primary component, others describe the material simply as "Hyaluronic Acid" or "Sodium Hyaluronate Acid." This variation suggests a heterogeneous market where the chemical structure and cross-linking agent, such as BDDE, must be explicitly confirmed. Sourcing strategies should prioritize suppliers who clearly define the specific dermal filler type, such as "Fine Derm Deep Subskin," to ensure the product matches the intended clinical or aesthetic procedure.

Product Scope and Observed Listing Signals

Buyers should analyze the physical form and packaging details to validate the authenticity of the injectable product claims. The data indicates a split between "Gel" and "Liquid" forms, with packaging ranging from "Pre-Filled in The Glass Syringer B. D" to "One Prefilled Syringe with Two Sterile Needles." These specific packaging configurations are critical indicators of a sterile, ready-to-use medical device rather than a generic cosmetic cream. Procurement teams must verify that the listed "Pre-Filled" status aligns with the sterile requirements for injection, ensuring the packaging integrity is maintained from the factory to the point of use.

The observed volume ranges and model specifications provide further signals regarding the product's intended anatomical application. Listings mention specific volumes like "1ml, 2ml" for deep dermal use and "10ml, 20ml" for subskin applications, alongside broader ranges up to "50ml." These volume distinctions are not merely marketing variations but reflect the viscosity and cross-linking density required for different tissue depths. Buyers must match the ordered volume and model, such as "Reyoungel Subskin," to the specific treatment protocol to avoid purchasing a product with incorrect rheological properties for the target procedure.

Technical Specifications to Verify

Verification of the chemical composition is the primary technical hurdle for sourcing these biological diagnostic reagents. The supplied facts list "Sodium Cross-Linked Hyaluronic Acid" and "Sodium Hyaluronate Acid Dermal Filler" as components, with "BDDE" identified as the cross-linking agent. Procurement teams must demand batch-specific certificates of analysis that confirm the exact concentration, such as the observed "24mg/Ml," and the purity of the cross-linking agent. Without this granular chemical data, the product cannot be reliably classified as a safe injectable dermal filler for human use.

The pH level and physical stability of the filler are equally critical parameters that must be confirmed against the observed range of 6.8 to 7.5. This specific pH window is essential for biocompatibility and minimizing tissue irritation upon injection. Buyers should require technical datasheets that explicitly state the pH value for each batch, as deviations can indicate degradation or improper formulation. Additionally, the "Chemical Synthesis" process noted in the data requires validation to ensure the manufacturing method consistently produces the required molecular weight and gel consistency for the specified "Deep Derm Filler" applications.

Compliance and Safety Documentation

Regulatory compliance is the most significant barrier to entry for sourcing injectable dermal fillers, particularly regarding the "CE" certification mentioned in the listings. While the data confirms the presence of CE and ISO certifications, buyers must verify that these marks apply specifically to the injectable device and not just the packaging or a different product line. The distinction between a cosmetic product and a medical device is legally defined by the intended use, and the certification must cover the "Injection & Puncture Instrument" classification to be valid for clinical procurement.

Safety documentation must also address the specific side effects and efficacy claims associated with the product. Although some listings state "No" side effects, this is a claim that requires robust clinical trial data and post-market surveillance reports to substantiate. Procurement teams should request the full technical file, including biocompatibility testing results and sterility assurance levels, to validate the safety profile. Relying solely on the "No" side effect claim without supporting documentation exposes the buyer to significant liability and potential regulatory action in the destination market.

Cost Drivers and Commercial Terms

The price range observed from 1.15 to 158 USD reflects a wide disparity in product quality, regulatory status, and volume. This variance suggests that lower-priced items may be non-injectable gels or unregulated cosmetic products, while higher-priced items likely represent certified medical devices with full documentation. Buyers must correlate the unit price with the specific certification level and volume, understanding that a compliant, sterile, injectable dermal filler will command a premium over generic alternatives. Cost analysis should never be based on the lowest price alone but on the total cost of compliance and risk mitigation.

Commercial terms such as Minimum Order Quantity (MOQ) and supply type significantly impact the procurement strategy. The observed MOQ range of 1 to 500 units allows for flexibility, but the "OEM/ODM" and "OEM Service" supply types indicate that many suppliers offer private labeling. Buyers should negotiate terms that include quality guarantees and clear liability clauses, especially when utilizing OEM services. The lead time and shipping conditions for sterile medical devices must also be factored into the total cost, as maintaining the cold chain and sterility during transit adds logistical complexity and expense.

Supplier Qualification and Quality Control

Supplier qualification requires a deep dive into the manufacturing process and the origin of the product. The data indicates the product origin is "China," and the process involves "Chemical Synthesis." Buyers must verify the supplier's facility certifications and their adherence to Good Manufacturing Practices (GMP) for medical devices. It is essential to confirm that the "Chemical Synthesis" process is conducted in a controlled environment that prevents contamination, ensuring the final "Sodium Cross-Linked Hyaluronic Acid" product meets the required purity standards.

Quality control protocols must be established to verify the consistency of the "Pre-Filled" syringes and the integrity of the "Blister Package" or "Strong Box" shipping containers. The presence of "Two Sterile Needles" with the syringe implies a specific assembly process that must be validated. Procurement teams should request audit reports or third-party inspection results that confirm the sterility of the needles and the accuracy of the fill volume. Without rigorous quality control checks, the risk of receiving non-sterile or under-filled products increases, which could compromise patient safety and the reputation of the buyer.

Long-Term Procurement Checks

Sustaining a reliable supply chain for injectable dermal fillers requires ongoing monitoring of product performance and regulatory updates. The "CE" certification and other standards are subject to renewal and potential changes in regulatory frameworks. Buyers must establish a schedule for re-verifying the supplier's certification status and ensuring that the product specifications, such as the "pH 6.8-7.5" range, remain consistent over time. Proactive monitoring prevents supply disruptions and ensures that the products remain compliant with evolving international medical device regulations.

Long-term procurement also involves tracking the shelf life and storage conditions of the "Pre-Filled" syringes to maintain product efficacy. The "Disposable" nature of the product means that any degradation during storage can render the entire batch unusable. Buyers should implement a first-expiry-first-out inventory system and regularly test the stability of the "Hyaluronic Acid" gel under various storage conditions. Continuous feedback loops with the supplier regarding any adverse events or quality issues are essential to maintain the safety and efficacy of the dermal filler supply over the long term.